The anti-CRC properties of liganded VDR largely rely on its capacity to interfere with a well-recognized CRC driver, the canonical Wnt/β-catenin signalling pathway that regulates many pro-tumoural genes and which is abnormally over-activated in most CRC 17. The gene discussed is VDR; the disease is colorectal carcinoma.